Cablivi® (caplacizumab-yhdp) – New orphan drug approval
February 6, 2019 - The FDA announced the approval of Sanofi’s Cablivi (caplacizumab-yhdp), for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Top